Welcome to our dedicated page for Phathom Pharmaceuticals news (Ticker: PHAT), a resource for investors and traders seeking the latest updates and insights on Phathom Pharmaceuticals stock.
Phathom Pharmaceuticals, Inc. develops and commercializes treatments for gastrointestinal diseases, with news centered on VOQUEZNA® (vonoprazan), an oral potassium-competitive acid blocker. Company updates commonly cover VOQUEZNA commercialization for GERD, prescription trends, product presentations, clinical and real-world data, and vonoprazan use with antibiotics for H. pylori infection.
Recurring announcements also address financial results, expense discipline, balance-sheet actions, and guidance tied to the company's commercial execution. Phathom's pipeline-related updates include studies evaluating VOQUEZNA in eosinophilic esophagitis and publications or conference presentations involving GERD and non-erosive reflux disease.
Phathom Pharmaceuticals (Nasdaq: PHAT) reported Q2 2026 net revenue of $74.3 million, up 88% year over year and 27% sequentially, driven by VOQUEZNA, with about 325,000 prescriptions in the quarter and 1.7 million cumulatively.
Operating expenses fell to $63.1 million, down 33% versus Q2 2025, yielding near breakeven non-GAAP adjusted net loss of $0.1 million versus $56.5 million a year ago. Cash and equivalents were $182.5 million. Phathom plans a Phase 3 as-needed VOQUEZNA trial in Non-Erosive GERD starting Q4 2026 and expects Phase 2 EoE topline data in Q4 2026. Updated 2026 guidance sets net revenue at $310–325 million and non-GAAP operating expenses at $235–245 million, while maintaining gross margin and gross-to-net assumptions.
Phathom Pharmaceuticals (Nasdaq: PHAT) will host a live webcast on Thursday, July 30, 2026, at 8:00 am EDT to report its second quarter 2026 financial results and provide a business update.
The event will be accessible via the company’s website, with a recording available for 90 days.
Phathom Pharmaceuticals (Nasdaq: PHAT) completed patient enrollment ahead of schedule in its Phase 2 pHalcon-EoE-201 trial of VOQUEZNA (vonoprazan) for eosinophilic esophagitis in adults. The randomized, double-blind, placebo-controlled study enrolled 95 patients at 41 U.S. sites, with 12-week double-blind treatment plus a 12-week VOQUEZNA extension. Topline results are expected in Q4 2026.
Phathom Pharmaceuticals (Nasdaq: PHAT) announced participation in three upcoming investor conferences in May and June 2026.
Management will attend the Craig-Hallum 23rd Annual Institutional Investor Conference on May 28 in Minneapolis, the Jefferies Global Healthcare Conference on June 3 in New York, and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9 in Miami, including fireside chats and one-on-one meetings.
Phathom Pharmaceuticals (Nasdaq: PHAT) reported extensive vonoprazan research at Digestive Disease Week (DDW) 2026, with 31 clinical abstracts, including 28 independent studies and three Phathom-sponsored posters.
Topics covered GERD, H. pylori eradication, safety, post‑ESD care, and a Phase 3 pHalcon‑NERD‑301 analysis honored as a Poster of Distinction. VOQUEZNA® indications and detailed safety information were also highlighted.
Phathom Pharmaceuticals (Nasdaq: PHAT) will present VOQUEZNA® (vonoprazan) clinical and real-world data at Digestive Disease Week® (DDW) 2026 in Chicago, May 2–5. A product theater on VOQUEZNA is scheduled for May 4 at 12:00 PM CDT, and the company will exhibit at booth 2511.
Three poster presentations and post-meeting abstracts will be available on the company publications page.
Phathom Pharmaceuticals (Nasdaq: PHAT) reported Q1 2026 net revenues of $58.3 million, a 104% year-over-year increase, and approximately 1.35 million total VOQUEZNA prescriptions filled to date (as of April 17, 2026). Q1 operating expenses were $61.8 million and non-GAAP operating expenses were $56.2 million. The company reported a Q1 net loss of $30.4 million and non-GAAP adjusted net loss of $14.7 million. Cash and cash equivalents were $180.9 million as of March 31, 2026. Phathom maintained 2026 guidance: net revenues of $320–$345 million, gross-to-net 55–59%, gross margin ~80%, and non-GAAP operating expenses of $235–$255 million, with operating profitability expected beginning in Q3 2026.
Phathom Pharmaceuticals (Nasdaq: PHAT) will report first quarter 2026 financial results and provide a business update via live webcast on Thursday, April 30, 2026 at 8:00 am EDT.
A recording will be available for 90 days. Phathom commercializes vonoprazan as VOQUEZNA products for GERD and H. pylori in the U.S. More information is on the Events & Presentations section of the company website.
Phathom Pharmaceuticals (Nasdaq: PHAT) said members of its management team will participate in two investor conferences in April 2026: the Raymond James 2026 Biotech Innovation Symposium in New York on April 14, 2026 and the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026.
Management will hold one-on-one meetings and a Needham fireside chat at 1:30 pm EDT; webcasts and recordings will be available via the company website for 90 days.
H. pylori infections market (CPIX) is projected to expand from a USD 270 million market in 2025 at a 9.4% CAGR through 2036 across the 6MM. US holds ~85% of 2025 revenue and ~57 million diagnosed prevalent cases; emerging therapies such as rifasutenizol, linaprazan glurate, and tegoprazan are expected to reshape treatment paradigms with reported Phase III eradication rates >90% for some candidates.
Challenges include a limited pipeline, geographic regulatory gaps, rising antibiotic resistance, and adherence issues with high pill burdens.